Answers are grounded in this paper and cite their sources.
Viewpoint article discusses RNA-LNP instability, quantification methods, and drug product improvements.
LNPs are proven to be effective nanocarriers for delivering nucleic acid in vivo. The US FDA approval of multiple LNP‑based drug products catalyzed multiple clinical studies across disease indications covering various RNA modalities. However, the stability of LNPs has been a long‑lasting challenge. This Viewpoint article talks about reported observations of RNA‑LNP instability, methods to quantify, and ways to improve the drug product profile.
No takes yet. Share an insight, caveat, or question.
Pintu Kanjilal (2026) studied this question.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: